Here are the 10-K annual reports from Xeriant Inc (XERI) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XERI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XERI filings page.
Xeriant, Inc. (XERI) reported net income of $392,278 for the year ended June 30, 2026, compared with a net loss of $1,646,898 in fiscal 2025. Fiscal 2026 income included a $2,810,278 gain on extinguishment of debt.
Operating activities used $791,756 of cash, compared with $1,288,505 in fiscal 2025. Cash was $87,594 and the working capital deficit was $4,897,313 at June 30, 2026. Management estimated available cash would last approximately four months from that date, and management and the auditor stated substantial doubt about Xeriant’s ability to continue as a going concern. Xeriant recorded a $3,500,000 Auctus settlement liability and reported no cash payments under the settlement as of June 30, 2026; settlement terms were extended through October 31, 2026.
Xeriant remains a development-stage company with no sales. It reported completing 16 NexBoard certification tests as of the report date, and its patent covering proprietary technology was issued July 14, 2026.
Xeriant, Inc. reports significant liquidity and capital structure issues while advancing a new product initiative. The company had a $8,708,900 working capital deficit and notes that, based on historical spending, it expects to expend available cash in approximately three months from October 2, 2025, creating substantial doubt about its ability to continue as a going concern. The filing discloses 749,053,035 outstanding common shares and extensive convertible instruments: warrants totaling roughly 111,568,828 and 118,968,828 outstanding in different series and multiple convertible notes with low conversion prices and adjustment features. The company is developing NEXBOARD, a wallboard product that requires industry certification, and appointed two senior advisors in nanomaterials. Significant financing arrangements include a note from Auctus with conversion activity and related legal dispute, plus outstanding notes with conversion at $0.01 per share.